Simulations Plus, Inc.

Simulations Plus, Inc. develops software and consulting services used in biopharma research, drug development, clinical trials, and commercialization. The company is based in the United States and operates through wholly owned subsidiaries, serving customers globally across the drug development lifecycle.

−79,0 %

58,4 %

−81,7 %

+13,1 %

7.67

7.67

— Simulations Plus, Inc.
%
Software58% Scientific software platforms used for biosimulation, modeling, and drug development workflows.
Services42% Consulting, customization, and expert support for drug discovery and development programs.

Customers are primarily biopharma organizations that use modeling and simulation to improve drug discovery,...

  • Pharmaceutical companiesprimary

    Buy software and consulting to support discovery, clinical development, and commercialization decisions.

  • Biotechnology companiesprimary

    Use the platform and expert services to supplement limited internal modeling resources.

  • Research institutions and government organizationssecondary

    Use the software for scientific research, training, and applied drug-development studies.

  • Non-pharma industriesemerging

    Agrotechnology and cosmetics customers use selected tools for modeling and scientific analysis.

The company markets its software and services globally, with sales and marketing activity spanning scientific meetings,...

  • •United States is the corporate base and a major operating market
  • •Global commercial reach through scientific meetings and direct sales
  • •Independent distributors in Japan, China, India, South Korea, and Brazil
  • •International pharma hubs matter because customers are research-intensive
  • •Regulatory and scientific adoption varies by region and affects demand

The company is focused on expanding use of its software and services across the full drug development lifecycle, from...

01
Expand existing client relationshipsshort-term

Deeper adoption increases software and services revenue per account and strengthens retention.

02
Account-based solution sellingshort-term

Selling integrated solutions improves relevance to client pain points and supports scalable growth.

03
Strategic acquisitions and partnershipsmedium-term

External growth can add capabilities, customers, and market access in adjacent areas.

Demand depends on continued acceptance of model-informed drug development, regulatory support, and customers'...

high

Limited adoption of model-informed drug development

If regulators or academic institutions resist these methods, demand for the company's tools and services can weaken.

Scope
Biopharma software and consulting demand
Materiality
high
high

Competitive pressure from larger and adjacent providers

Competitors include established software firms, CROs, consulting groups, and in-house pharma teams with greater resources.

Scope
Software licenses and consulting engagements
Materiality
high
high

Dependence on client budgets and outsourcing decisions

Customers may reduce spending or bring work in-house, lowering software and services demand.

Scope
Pharma and biotech customer base
Materiality
high
medium

AI and machine learning deployment risk

Flawed models, poor datasets, or harmful outputs could damage reputation and create legal or regulatory exposure.

Scope
AI-augmented software and analytics
Materiality
medium
Revenue recognition
Affects quarterly revenue mix and comparability
Capitalized software development costs
Impacts operating expense and intangible assets
Goodwill and intangible assets
Can create non-cash impairment charges
Stock-based compensation
Affects reported profitability and dilution

Certara, Inc.

CERT · Services-Prepackaged Software

HARVARD BIOSCIENCE INC

HBIO · Laboratory Analytical Instruments

Healthcare AI Acquisition Corp.

Blank Checks

Absci Corp

ABSI · Services-Commercial Physical & Biological Research

BNB PLUS CORP.

BNBX · Finance Services

BullFrog AI Holdings, Inc.

BFRG · Pharmaceutical Preparations

: 29/04/2026